Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Cancers|July 2, 2021
Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaOndine Becquart, Bastien Oriano, Stéphane Dalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> <sup>V600MUT</sup> Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Matthieu Resche-Rigon, Thierry Lesimple, et al.
The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
The Lancet. Oncology|June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialMichael A Davies, Philippe Saiag, Caroline Robert, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2022
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint-Ghislain, Anne-Céline Derrien, Lionnel Geoffrois, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Pageof 8